H.C. Wainwright assumed coverage of Travere Therapeutics (TVTX) with a Buy rating and $30 price target The primary focus is the Filspari commercial launch in the U.S., which is now the only fully approved, non-immunosuppressing, kidney-targeted therapy positioned to potentially replace standard of care, the analyst tells investors in a research note. The firm says Filspari looks to leverage a key opportunity to move into earlier lines of therapy for IgAN.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Buy Rating for Travere Therapeutics: Anticipated FDA Approval and Strategic Developments Signal Significant Upside Potential
- Citi trims Travere target, opens ‘upside 90-day catalyst watch’
- Cito trims Travere target, opens ‘upside 90-day catalyst watch’
- Buy Rating for Travere Therapeutics Amid Filspari’s FDA Review and Market Potential
- Travere Therapeutics Holds Annual Meeting, Elects Directors
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue